bit.bio
Engineering human cells for research and drug discovery using synthetic biology and gene programming.
bit.bio is a biotech & life sciences company. It has raised $25 million in disclosed funding. Its latest round was a Series D of $25 million in November 2026.
Overview
Bit.bio is a biotechnology company that engineers human cells for use in biomedical research and drug discovery [0, 2]. Spun out of the University of Cambridge in 2016, the firm utilizes a proprietary platform that leverages high-throughput screening and data analysis to identify specific transcription factor combinations for cellular programming [2]. The company commercializes a wide range of human cells and disease models—such as nerve, immune, and muscle cells—under its ioCells brand, allowing scientists to scale experiments without the constraints of traditional cell sourcing [1, 2]. Additionally, bit.bio provides CRISPR-based functional genomics screening services to assist researchers from concept to results [0]. The company is currently operating at the Series C+ stage and has recorded $25 million in funding [Registry].
Funding
Total disclosed: $25M across 1 round. Computed only from sourced rounds.
Investors
Questions and answers
What does bit.bio do?
Engineering human cells for research and drug discovery using synthetic biology and gene programming.
How much has bit.bio raised?
bit.bio has raised $25 million in disclosed funding across 1 round tracked by OSH.
Who has invested in bit.bio?
Investors in bit.bio include M&G Investments and Dr Jonathan Milner.
Sources
- 1.Human cell programming company bit.bio closes $25M Series D — Tech.eu, Nov 4, 2026
- 2.bit.bio · Official
- 3.bit.bio · Official
- 4.bit.bio · Official